Corient Private Wealth LP Sells 5,600 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Corient Private Wealth reduced its Regeneron stake by 31% in the second quarter, selling 5,600 shares and retaining 12,473 shares valued at approximately $7.8 million.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $802.18; the company also pays a quarterly dividend of $0.94, yielding about 0.5%.

Corient Private Wealth LP lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 31.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,473 shares of the biopharmaceutical company's stock after selling 5,600 shares during the period. Corient Private Wealth LP's holdings in Regeneron Pharmaceuticals were worth $7,779,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in REGN. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $789.45 on Friday. The stock's fifty day moving average price is $764.43 and its two-hundred day moving average price is $720.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The firm has a market cap of $81.28 billion, a PE ratio of 19.51, a PEG ratio of 1.52 and a beta of 0.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.81 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur Ryan sold 200 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company's stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on REGN shares. Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a research note on Wednesday, July 29th. Leerink Partners raised their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research report on Monday, August 17th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 12th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.